alexan 100
pharmalogic ltd - cytarabine 100 mg / 5 ml - solution for injection - cytarabine - for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas ( non-hodgkin's lymphomas of high malignancy).
gemcitabin " ebewe " 200 mg
pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
gemcitabin " ebewe " 200 mg
pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
gemcitabin "ebewe" 1 g
pharmalogic ltd - gemcitabine as hydrochloride 1000 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
gemcitabin "ebewe" 1 g
pharmalogic ltd - gemcitabine as hydrochloride 1000 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
gemcitabin "ebewe" 10 mg/1 ml
pharmalogic ltd - gemcitabine as hydrochloride 10 mg - concentrate for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
carboplatin "ebewe" 10 mg/ml
pharmalogic ltd - carboplatin 10 mg/ml - solution for infusion - carboplatin - carboplatin is used alone or in combination with other antineoplastic agents in the treatment of advanced ovarian carcinoma and metastatic small cell lung cancer.
oxaliplatin "ebewe" 50 mg
pharmalogic ltd - oxaliplatin 50 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.
oxaliplatin "ebewe" 100 mg
pharmalogic ltd - oxaliplatin 100 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.
oxaliplatin "ebewe" 150 mg
pharmalogic ltd - oxaliplatin 150 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.